Pfizer and Eisai Continue Aricept Collaboration
Companies also enter into new collaboration to co-promote Lyrica in Japan
(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights. Pfizer will maintain its rights in all countries where it currently commercializes Aricept until July 2022, with the exception of Japan. Pfizer will now return the rights to Aricept in Japan, to Eisai on December 31, 2012.
Pfizer and Eisai have also entered into a new agreement effective today to co-promote Lyrica in Japan. Lyrica is under regulatory review in Japan, and assuming approval is granted, this agreement will continue in force until July 2022.
“Our continued partnership with Eisai is a testament to Pfizer’s commitment to help patients suffering from Alzheimer’s disease,” said Jeff Kindler, Pfizer Chairman and Chief Executive Officer. “In addition, we look forward to forging a new alliance with Eisai to help treat neuropathic pain with our co-promotion of Lyrica in Japan following regulatory approval.”
Pfizer Inc: Working together for a healthier world™
Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.